Primary Mitochondrial Myopathy Clinical Trial
Official title:
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
This is a randomized, double-blind, placebo-controlled, parallel group, multi-centre, study designed to investigate the efficacy and safety of REN001 administered once daily over a 24-week period to patients with PMM.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03323749 -
A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
|
Phase 3 | |
| Active, not recruiting |
NCT04641962 -
A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy
|
Phase 2/Phase 3 | |
| Terminated |
NCT03862846 -
A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy
|
Phase 1 | |
| Terminated |
NCT05267574 -
An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)
|
Phase 2/Phase 3 |